knowledge -WSS

knowledge

author：knowledge 2025-09-29 16:34:28 - browse：8

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Researchers test human milk's ability to repair gut microbiome

focus

WSS

A letter from the executive editor: The 2023 STATUS List

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Harvard scientists, with Google, unveil the most detailed brain map ever

Multiple sclerosis has subtypes with different best treatments: study

Covid silver lining: Unprecedented look at human immune system

Bird flu in dairy cattle: New measures to control spread to humans

focus

knowledge

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Beware reading your test results before your doctor does

What does generative AI mean for health care? We asked experts

Young boy dies in trial for Pfizer Duchenne gene therapy

How to save PrEP access — and even expand it

Young boy dies in trial for Pfizer Duchenne gene therapy

Continuity nursing helped my family in our darkest PICU moments

AstraZeneca lung cancer study comes in below expectations

Psychedelics group wrestles with new pharma identity

Drug companies' payments and gifts affect physicians' prescribing

explore

Overprescribed: High cost isn't America's only drug problem

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Lupron, used to halt puberty in children, may cause lasting health problems

AstraZeneca lung cancer study comes in below expectations

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Security flaws in third

entertainment

hotspot

focus

knowledge